Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 368

Showing 1-25 of 368 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 380
mRNA vaccines in disease prevention and treatment
Gang Zhang, Tianyu Tang, Yinfeng Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 90
mRNA vaccines for cancer immunotherapy
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 81
Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications
Michaela Jeong, Yeji Lee, Jeongeun Park, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 114990-114990
Closed Access | Times Cited: 80
The use of RNA-based treatments in the field of cancer immunotherapy
Mohammad Chehelgerdi, Matin Chehelgerdi
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 74
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
Yu‐Shiuan Wang, Monika Kumari, Guanhong Chen, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 62
mRNA in the Context of Protein Replacement Therapy
Theofanis Vavilis, Εleni Stamoula, Alexandra Ainatzoglou, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 166-166
Open Access | Times Cited: 61
Lipid nanoparticle-mediated drug delivery to the brain
Purva Khare, Sara X. Edgecomb, Christine M. Hamadani, et al.
Advanced Drug Delivery Reviews (2023) Vol. 197, pp. 114861-114861
Closed Access | Times Cited: 55
Aptamer-Based Targeted Delivery of Functional Nucleic Acids
Sitao Xie, Weidi Sun, Ting Fu, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 14, pp. 7677-7691
Closed Access | Times Cited: 51
Recent Advancement in mRNA Vaccine Development and Applications
Nojoud AL Fayez, Majed S. Nassar, Abdullah A. Alshehri, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1972-1972
Open Access | Times Cited: 51
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Dimitrios Bitounis, Eric Jacquinet, Maximillian A. Rogers, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 281-300
Closed Access | Times Cited: 50
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
Bolin Wang, Jinli Pei, Shengnan Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 49
Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer
Shiyan Dong, Xuan Liu, Ye Bi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 41
Claudin 18.2 as a novel therapeutic target
Izuma Nakayama, Changsong Qi, Yang Chen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 5, pp. 354-369
Closed Access | Times Cited: 38
Chemically Modified Platforms for Better RNA Therapeutics
Yesi Shi, Xueyan Zhen, Yiming Zhang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 3, pp. 929-1033
Closed Access | Times Cited: 34
Exosome-mediated delivery and regulation in neurological disease progression
Gurpreet Singh, Ankit Mehra, Sanchit Arora, et al.
International Journal of Biological Macromolecules (2024) Vol. 264, pp. 130728-130728
Open Access | Times Cited: 19
Fluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency
Huipeng Zhang, Chaoyang Meng, Xuewen Yi, et al.
ACS Nano (2024) Vol. 18, Iss. 11, pp. 7825-7836
Closed Access | Times Cited: 17
Breaking the mold with RNA—a “RNAissance” of life science
Charles H. Jones, John R. Androsavich, N. So, et al.
npj Genomic Medicine (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 14
AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery
Yue Xu, Shihao Ma, Haotian Cui, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
mRNA Technology in Modern Medicine: Review and Future Prospects
Heslley Machado Silva
Deleted Journal (2025) Vol. 2, pp. 1-1
Closed Access | Times Cited: 1
mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
Vivek P. Chavda, Shailvi Soni, Lalitkumar K. Vora, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2150-2150
Open Access | Times Cited: 62
Lipid carriers for mRNA delivery
Wanting Zhang, Yuxin Jiang, Yonglong He, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 10, pp. 4105-4126
Open Access | Times Cited: 55
Development of mRNA vaccines against respiratory syncytial virus (RSV)
Xirui Qiu, Siyan Xu, Yang Lu, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 68, pp. 37-53
Closed Access | Times Cited: 43
Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities
Defeng Li, Qisong Liu, Meifeng Yang, et al.
Bioengineering & Translational Medicine (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 34
Chemical Modifications of mRNA Ends for Therapeutic Applications
Marcin Warmiński, Adam Mamot, Anaïs Depaix, et al.
Accounts of Chemical Research (2023) Vol. 56, Iss. 20, pp. 2814-2826
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top